A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Digestive Health and Surgery -
Location
-
Principal Investigator
-
Sponsor
Lilly USA
This study is being done to help answer the following research questions: (a) How mirikizumab, an investigational drug, could help people with ulcerative colitis over time; (b) How safe long-term use of mirikizumab is; and (c) To monitor any possible side effects of long-term use of mirikizumab.